PF-00446687 is a drug developed by Pfizer for the treatment of erectile dysfunction which is a non-peptide agonist selective for the melanocortin receptor subtype MC4. It was found to be active in preliminary human trials with the 200mg dose being of similar effectiveness to 100mg sildenafil though lower doses were ineffective.
This page contains content from the copyrighted Wikipedia article "PF-00446687"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
